Anemia News and Research

RSS

Anemia is a decrease in normal number of red blood cells (RBCs) or less than the normal quantity of hemoglobin in the blood. However, it can include decreased oxygen-binding ability of each hemoglobin molecule due to deformity or lack in numerical development as in some other types of hemoglobin deficiency. The three main classes of anemia include excessive blood loss (acutely such as a hemorrhage or chronically through low-volume loss), excessive blood cell destruction (hemolysis) or deficient red blood cell production (ineffective hematopoiesis). Anemia is the most common disorder of the blood. There are several kinds of anemia, produced by a variety of underlying causes. Anemia can be classified in a variety of ways, based on the morphology of RBCs, underlying etiologic mechanisms, and discernible clinical spectra, to mention a few.

Affymax receives arbitration panel decision related to dispute against JNJ subsidiaries

Affymax, Inc. today announced that it has received a decision from the arbitration panel reviewing its dispute against certain subsidiaries of Johnson and Johnson (JNJ).

7 Oct 2010

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

Ferring Pharmaceuticals Inc. today announced publication of one of its pivotal Phase 3 trials of LYSTEDA (tranexamic acid) tablets for cyclic heavy menstrual bleeding in the October issue of the peer-reviewed journal, Obstetrics & Gynecology. The six-month clinical trial demonstrated that LYSTEDA significantly reduced menstrual blood loss from baseline, and improved health-related quality-of-life parameters in women with cyclic HMB while maintaining safety and tolerability.

7 Oct 2010

New report focuses on management of renal anemia amongst dialysis, later stage CKD patients

BioTrends Research Group, Inc. recently published its TreatmentTrends: Renal Anemia in China report. This report is based on survey results from 150 nephrologists in clinical practice in China and qualitative interviews conducted with ten thought leaders in nephrology. The report examines the demographics of nephrology practice in China and focuses specifically on the management of renal anemia amongst dialysis and later stage chronic kidney disease patients.

7 Oct 2010

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Nautilus Neurosciences, Inc., a neurology-focused specialty pharmaceutical company, and Mission Pharmacal Company, a privately-held pharmaceutical company focused on the women's health market announced today their exclusive co-promotion agreement for CAMBIA (diclofenac potassium for oral solution) to obstetrician's, gynecologists and other women's health medical professionals.

6 Oct 2010

Miller-Mccune examines impact of limited access to schistosomiasis drug in Africa

Miller-McCune examines the limited access populations living in Africa have to the schistosomiasis drug praziquantel the only commercially available treatment for the disease.

6 Oct 2010

Amgen to present oncology portfolio results at ESMO Congress

Amgen today announced that results from several important studies from the Company's ncology portfolio will be presented at the 35th European Society for Medical Oncology (ESMO) Congress, Oct. 8-12, 2010, in Milan, Italy.

6 Oct 2010

Dr. Bessler joins Children's Hospital of Philadelphia

One of the world's leading experts in bone marrow failure and related blood disorders recently joined The Children's Hospital of Philadelphia. Hematology researcher Monica Bessler, M.D., Ph.D., arrived at the hospital this summer to establish a new program, the Pediatric and Adult Comprehensive Bone Marrow Failure Center.

5 Oct 2010

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck & Co., Inc. today said it will appeal a decision by the U.S. District Court for the Southern District of New York that reduced the jury verdict from $8 million to $1.5 million but denied Merck's request for judgment in its favor or a new trial in the case of Boles v. Merck, a retrial of a federal FOSAMAX case.

5 Oct 2010

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Merck today announced that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, will be presented in oral plenary sessions at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), which is taking place from Oct. 29 through Nov. 2 in Boston. Results for boceprevir in response-guided therapy strategies, which evaluated treatment durations shorter than current standard therapy, will be presented during the meeting.

4 Oct 2010

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

Sanofi-aventis announced today that data from the Phase III TROPIC study, which was the basis for the June 2010 U.S. Food and Drug Administration (FDA) approval of Jevtana (cabazitaxel) Injection, was published in the October 2, 2010 print edition of The Lancet in an article titled "Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial.

4 Oct 2010

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

In just 21 days, CVS/pharmacy's ninth annual in-store fundraising campaign to support the fight against amyotrophic lateral sclerosis (ALS) brought in $4.1 million. The funds raised by the campaign will be donated to the Boston-based ALS Therapy Alliance (ATA) to support the funding of new clinical research aimed at developing new therapies for ALS patients and focused on the ultimate goal of finding a cure for ALS.

1 Oct 2010

DaVita announces $1.45 billion Senior Notes offering

DaVita Inc. announced today that it intends to offer, subject to market and other conditions, $1.45 billion principal amount of senior notes (the "Senior Notes").

1 Oct 2010

Center for Excellence in Sickle Cell Disease established by Vanderbilt and Meharry

A Vanderbilt-Meharry Center for Excellence in Sickle Cell Disease has been established by Vanderbilt University Medical Center and Meharry Medical College. The Center will seek to bring high quality care to people with sickle cell disease (SCD) that is seamless and lifelong.

1 Oct 2010

Celiac disease on the rise in adults: Study

According to a new study published Monday in the Annals of Medicine, cases of intestinal disorder known as Celiac disease are on the rise with many adults developing the disease.

28 Sep 2010

OrSense introduces NBM200 system for anemia screening, hemorrhage detection

OrSense Ltd., developer of monitors for non-invasive measurements of various blood parameters, introduced at the Global Forum of Maternal and Infant Health, at Barcelona, Spain, NBM200, a non-invasive hemoglobin measurement system for anemia screening and hemorrhage detection. The Company presented results showing that Hb measurements obtained by the NBM200 showed accurate performance compared with invasive point of care devices.

27 Sep 2010

Double-Balloon Enteroscopy shows potential benefits in children

The use of device assisted enteroscopy, a technique that allows complete examination of the small bowel, may be just as successful pediatrics as it has been in adult medicine, according to a study from Nationwide Children's Hospital.

27 Sep 2010

Amgen announces voluntary recall of certain lots of EPOGEN and PROCRIT

Amgen announced today that certain lots of EPOGEN® and PROCRIT® (Epoetin alfa) vials are being voluntarily recalled from specialty distributors, wholesalers, pharmacies and healthcare providers as a precaution. The product that is being recalled may contain extremely thin glass flakes (lamellae) that are barely visible in most cases. The lamellae result from the interaction of the formulation with glass vials over the shelf life of the product.

24 Sep 2010

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Following today’s announcements by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for rosiglitazone in the U.S. and Europe, Takeda Pharmaceuticals North America, Inc. and Takeda Pharmaceuticals Europe Limited underscore the company’s commitment to ACTOS® (pioglitazone HCl) and ACTOS-containing medications, and to the millions of people living with type 2 diabetes.

24 Sep 2010

Weight-based taribavirin reduces anemia, increases sustained virologic response

Researchers at Cedars-Sinai Medical Center and 50 other centers found that weight-based dosing of taribavirin reduces rates of anemia while increasing sustained virologic response (SVR) in patients with chronic hepatitis C (HCV). Full details of this study are available in the October issue of Hepatology, a journal published by Wiley-Blackwell on behalf of the American Association for the Study of Liver Diseases (AASLD).

23 Sep 2010

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Among patients receiving immunosuppressive therapy for severe aplastic anemia (a condition in which the bone marrow is unable to produce blood cells), the length of telomeres (chromosome markers of biological aging) was not related to the response to treatment but was associated with a higher rate of relapse (return to low blood cell counts) and lower overall survival, according to a study in the September 22/29 issue of JAMA.

22 Sep 2010

Anemia News and Research

Further Reading

Affymax receives arbitration panel decision related to dispute against JNJ subsidiaries

Ferring Pharmaceuticals announces publication of Phase 3 trials of LYSTEDA tablets for HMB

New report focuses on management of renal anemia amongst dialysis, later stage CKD patients

Nautilus Neurosciences announces exclusive co-promotion agreement for CAMBIA drug

Miller-Mccune examines impact of limited access to schistosomiasis drug in Africa

Amgen to present oncology portfolio results at ESMO Congress

Dr. Bessler joins Children's Hospital of Philadelphia

Merck to appeal against jury verdict in retrial of federal FOSAMAX case

Merck's boceprevir Phase III studies for HCV to be presented at 61st AASLD

Sanofi-aventis publishes Phase III TROPIC study data in The Lancet article

CVS/pharmacy's fundraising campaign raises $4.1 million for ALS research

DaVita announces $1.45 billion Senior Notes offering

Center for Excellence in Sickle Cell Disease established by Vanderbilt and Meharry

Celiac disease on the rise in adults: Study

OrSense introduces NBM200 system for anemia screening, hemorrhage detection

Double-Balloon Enteroscopy shows potential benefits in children

Amgen announces voluntary recall of certain lots of EPOGEN and PROCRIT

Takeda underscores commitment to ACTOS following FDA and EMA announcements for rosiglitazone

Weight-based taribavirin reduces anemia, increases sustained virologic response

Telomere length associated with higher rate of relapse and lower overall survival in aplastic anemia patients

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News